# Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?

**Authors:** Timothy M. Schmidt

PMC · DOI: 10.1038/s41408-024-01070-2 · 2024-06-04

## Full-text entities

- **Genes:** CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}
- **Diseases:** extramedullary disease (MESH:D023981), MM (MESH:D009101), HRCA (MESH:D002869), plasma cell leukemia (MESH:D007952), toxicity (MESH:D064420)
- **Chemicals:** isatuximab (MESH:C000599209), steroids (MESH:D013256), DaraKRd (-), lenalidomide (MESH:D000077269), dexamethasone (MESH:D003907), plerixafor (MESH:C088327), carfilzomib (MESH:C524865), daratumumab (MESH:C556306)
- **Species:** Homo sapiens (human, species) [taxon 9606]

---
Source: https://tomesphere.com/paper/PMC11150380